MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
29.60
+1.79
+6.44%
Pre Market: 29.35 -0.25 -0.84% 08:33 12/05 EST
OPEN
27.68
PREV CLOSE
27.81
HIGH
29.71
LOW
27.68
VOLUME
2
TURNOVER
0
52 WEEK HIGH
29.71
52 WEEK LOW
14.40
MARKET CAP
1.97B
P/E (TTM)
-8.7527
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLDX last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at CLDX last week (1117-1121)?
Weekly Report · 11/24 09:56
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
Seeking Alpha · 11/19 20:01
Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
Reuters · 11/18 21:26
Ex-Celldex Officer Cashes Out Big with Stock Sale!
TipRanks · 11/18 02:07
Weekly Report: what happened at CLDX last week (1110-1114)?
Weekly Report · 11/17 09:56
Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating
TipRanks · 11/13 11:56
Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver
Reuters · 11/12 21:06
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.